Changes in Body Image in Patients with Prostate Cancer over 2 Years of Treatment with a Gonadotropin-Releasing Hormone Analogue (Triptorelin): Results from a Belgian Non-Interventional Study.

van den Driessche H, Mattelaer P, van Oyen P, Marchand W, Bar-Moshé O, Merckx L, Billiet I, Cabri P, Maisonobe P, De Ruyter V, Braeckman J

Drugs - real world outcomes13 May 2016Cited by 4 (Europe PMC)

PMID27398297PMCIDPMC4914546DOI10.1007/s40801-016-0074-5PepBankPUB-27398297

Read at source PubMedAsk about this study

Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

01HumanObservational studyEfficacy outcome
In prostate cancer patients receiving triptorelin, BMI changes were modest and generally not statistically significant.
In plain wordsIn prostate cancer patients receiving triptorelin, BMI changes were modest and generally not statistically significant.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
No significant changeBMI change
Study
n = 98
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · 2 yearsAs given in this study (human).
Source sentences
Summary
Changes in BMI from baseline were modest and generally not statistically significant.
3 context sentences(design, population, supporting numbers)
Summary · context
Body image and physical presentation changes were investigated in patients receiving a gonadotropin-releasing hormone analogue (triptorelin) as part of treatment for locally advanced or metastatic prostate cancer.
Summary · context
Data were collected for 2 years in accordance with routine clinical practice.
Summary · context
BIS and BMI data for both baseline and a least one post-baseline visit were available for 98 of the 145 patients enrolled.
Report a problemFND-2739829704
02HumanObservational studyEfficacy outcome
In prostate cancer patients receiving triptorelin, median body image score change was zero around 12 and 24 months and last observation.
In plain wordsIn prostate cancer patients receiving triptorelin, median body image score change was zero around 12 and 24 months and last observation.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
Direction not reportedMedian body image score change
Study
n: not reported in source
Outcome group
Patient-reported outcomes · Mental health and mood
Studied dose
Dose not stated · 2 yearsAs given in this study (human).
Measurements
Median BIS change
0 score
around 12 or 24 months and last observation
Source sentences
Summary
The median change in BIS score for patients assessed around 12 or 24 months after baseline and at the last observation was zero, indicating no body image deterioration in at least half of patients.
3 context sentences(design, population, supporting numbers)
Summary · context
Body image and physical presentation changes were investigated in patients receiving a gonadotropin-releasing hormone analogue (triptorelin) as part of treatment for locally advanced or metastatic prostate cancer.
Summary · context
Data were collected for 2 years in accordance with routine clinical practice.
Summary · context
BIS and BMI data for both baseline and a least one post-baseline visit were available for 98 of the 145 patients enrolled.
Report a problemFND-2739829701
03HumanObservational studyEfficacy outcome
In prostate cancer patients, triptorelin treatment was associated with increased body image scores around 6, 12 and 18 months.
In plain wordsIn prostate cancer patients receiving triptorelin, body image scores increased around 6, 12 and 18 months, indicating worse body image.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
IncreaseBody image score increases
Study
n: not reported in source
Outcome group
Patient-reported outcomes · Mental health and mood
Studied dose
Dose not stated · 2 yearsAs given in this study (human).
Source sentences
Summary
Statistically significant BIS score increases were detected in assessments around 6, 12 and 18 months, but not after 2 years, indicating some patients experienced body image deterioration at some point during treatment.
3 context sentences(design, population, supporting numbers)
Summary · context
Body image and physical presentation changes were investigated in patients receiving a gonadotropin-releasing hormone analogue (triptorelin) as part of treatment for locally advanced or metastatic prostate cancer.
Summary · context
Data were collected for 2 years in accordance with routine clinical practice.
Summary · context
BIS and BMI data for both baseline and a least one post-baseline visit were available for 98 of the 145 patients enrolled.
Report a problemFND-2739829702
04HumanObservational studyEfficacy outcome
In prostate cancer patients receiving triptorelin, body image score increases were not significant after 2 years.
In plain wordsIn prostate cancer patients receiving triptorelin, body image score increases were not significant after 2 years.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
No significant changeBody image score at two years
Study
n: not reported in source
Outcome group
Patient-reported outcomes · Mental health and mood
Studied dose
Dose not stated · 2 yearsAs given in this study (human).
Source sentences
Summary
Statistically significant BIS score increases were detected in assessments around 6, 12 and 18 months, but not after 2 years, indicating some patients experienced body image deterioration at some point during treatment.
3 context sentences(design, population, supporting numbers)
Summary · context
Body image and physical presentation changes were investigated in patients receiving a gonadotropin-releasing hormone analogue (triptorelin) as part of treatment for locally advanced or metastatic prostate cancer.
Summary · context
Data were collected for 2 years in accordance with routine clinical practice.
Summary · context
BIS and BMI data for both baseline and a least one post-baseline visit were available for 98 of the 145 patients enrolled.
Report a problemFND-2739829703
05HumanObservational studyEfficacy outcome
In prostate cancer patients, triptorelin treatment was associated with increased waist circumference.
In plain wordsIn prostate cancer patients, triptorelin treatment was linked to increased waist circumference.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
IncreaseWaist circumference
Study
n: not reported in source
Outcome group
Body composition · Metabolic and weight
Studied dose
Dose not stated · 2 yearsAs given in this study (human).
Measurements
Mean waist circumference increase
1 cm
last observation
Source sentences
Summary
Waist circumference increased during the study (mean ± standard deviation increase of 1.00 ± 5.01 cm at the last observation).
3 context sentences(design, population, supporting numbers)
Summary · context
Body image and physical presentation changes were investigated in patients receiving a gonadotropin-releasing hormone analogue (triptorelin) as part of treatment for locally advanced or metastatic prostate cancer.
Summary · context
Data were collected for 2 years in accordance with routine clinical practice.
Summary · context
BIS and BMI data for both baseline and a least one post-baseline visit were available for 98 of the 145 patients enrolled.
Report a problemFND-2739829705

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.